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Kidney
Selective Endothelin-A Receptor Antagonism Reduces
Proteinuria, Blood Pressure, and Arterial Stiffness in
Chronic Proteinuric Kidney Disease
Neeraj Dhaun, Iain M. MacIntyre, Debbie Kerr, Vanessa Melville, Neil R. Johnston, Scott Haughie,
Jane Goddard, David J. Webb
Abstract—Proteinuria is associated with adverse cardiovascular and renal outcomes that are not prevented by current treatments.
Endothelin 1 promotes the development and progression of chronic kidney disease and associated cardiovascular disease. We,
therefore, studied the effects of selective endothelin-A receptor antagonism in proteinuric chronic kidney disease patients,
assessing proteinuria, blood pressure (BP), and arterial stiffness, key independent, surrogate markers of chronic kidney disease
progression and cardiovascular disease risk. In a randomized, double-blind, 3-way crossover study, 27 subjects on
recommended renoprotective treatment received 6 weeks of placebo, 100 mg once daily of sitaxsentan, and 30 mg once daily
of nifedipine long acting. Twenty-four–hour proteinuria, protein:creatinine ratio, 24-hour ambulatory BP, and pulse wave
velocity (as a measure of arterial stiffness) were measured at baseline and week 6 of each treatment. In 13 subjects, renal blood
flow and glomerular filtration rate were assessed at baseline and week 6 of each period. Compared with placebo, sitaxsentan
reduced 24-hour proteinuria (0.560.20 g/d; P0.0069), protein:creatinine ratio (3815 mg/mmol; P0.0102), BP
(3.41.2 mm Hg; P0.0069), and pulse wave velocity (0.640.24 m/s; P0.0052). Nifedipine matched the BP and
pulse wave velocity reductions seen with sitaxsentan but did not reduce proteinuria. Sitaxsentan alone reduced both
glomerular filtration rate and filtration fraction. It caused no clinically significant adverse effects. Endothelin-A receptor
antagonism may provide additional cardiovascular and renal protection by reducing proteinuria, BP, and arterial stiffness in
optimally treated chronic kidney disease subjects. The antiproteinuric effects of sitaxsentan likely relate to changes in BP and
renal hemodynamics. (Hypertension. 2011;57:772-779.) ● Online Data Supplement
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Chronic kidney disease (CKD) is common, affecting 6%to 11% of the population globally.1 It is strongly asso-
ciated with incident cardiovascular disease (CVD).2 Protein-
uria is a common feature of CKD, and the degree of
proteinuria is closely associated with renal outcome and
cardiovascular events.3 Importantly, a reduction in protein-
uria is associated with a slowing of both the decline in
glomerular filtration rate (GFR)3 and the progression to
end-stage renal disease.3 In addition, proteinuria reduction is
associated with an improved cardiovascular outcome in both
those with4 and without5 CKD. Thus, a reduction in protein-
uria is now widely accepted as a surrogate end point for
renoprotection.6 Current treatments for proteinuria focus on
blood pressure (BP) reduction, ideally using angiotensin-
converting enzyme (ACE) inhibitors and angiotensin receptor
blockers (ARBs),7 both of which are thought to reduce
proteinuria to a greater extent than accounted for by BP-
lowering alone.8 Nevertheless, many CKD patients have
significant residual proteinuria despite optimal treatment.9
Hypertension is a frequent finding in patients with CKD,10
and despite treatment with multiple antihypertensive agents,
the majority of CKD patients fail to reach target BP.11 In
addition to hypertension and proteinuria, arterial stiffness12
makes an important contribution to CVD risk in CKD. Thus,
there remains an unmet need for newer treatments in CKD
that will not only lower proteinuria and BP beyond the levels
achieved with standard therapies but also have favorable
effects on arterial stiffness and so offer longer-term cardio-
vascular and renal protection.
Endothelin (ET) 1 is implicated in both the development
and progression of CKD.13 ET-1 also contributes to arterial
stiffness in patients with CKD.14 The effects of ET-1 are
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mediated via 2 receptors, the ETA and ETB receptors, with
the major pathological effects in CKD being ETA receptor
mediated.13 However, there are currently few human stud-
ies in CKD.14 –17 The aim of the current study was to
evaluate whether the oral ETA receptor antagonist, sitax-
sentan, is able to reduce proteinuria, BP, and arterial
stiffness longer term in subjects with chronic nondiabetic
proteinuric kidney disease.
Methods
Subjects
We enrolled subjects 18 to 70 years of age with stable CKD stages
1 to 418 and proteinuria (300 mg/d). Subjects were on treatment
with ACE inhibitors and/or ARBs (but not necessarily diuretics) for
their proteinuria. Explicitly, doses of one or both of drugs were
titrated to the maximum tolerated, dependent on BP, renal function,
serum potassium levels, and adverse effects. All of the medications
were unchanged over the 3 months preceding the studies.
Patients with significant comorbidity, including diabetes mellitus,
heart or lung disease, and peripheral vascular disease, were excluded.
To enhance homogeneity and avoid other influences on vascular
reactivity, patients with vasculitis, other systemic inflammatory
disease, polycystic kidney disease, and nephrotic syndrome were
excluded. Furthermore, we excluded patients with abnormal liver
enzymes, hemoglobin 8 g/dL, and women of childbearing
potential.
Thirty-three patients with stable proteinuric CKD were screened,
and 27 were recruited into the studies. These were performed
between June 2007 and March 2009 in the University of Edinburgh
Clinical Research Centre with the approval of the local research
ethics committee and the written informed consent of each subject.
The investigations conformed to the principles outlined in the
Declaration of Helsinki.
Study Protocol
This was a single-center, 3-phase randomized, double-blind,
placebo-controlled crossover study. Its purpose was to investigate
the safety, tolerability, and efficacy of 100 mg of sitaxsentan once
daily versus placebo on reduction of proteinuria (primary end point),
BP, and arterial stiffness (cosecondary end points) in subjects with
CKD. Because previous studies with ET receptor antagonists have
shown a reduction in BP,19,20 and BP reduction may contribute to
changes in protein excretion and arterial stiffness, 30 mg of nifedi-
pine long acting (LA) once daily was used as an open-label active
control. Our choice of active control agent was based, most impor-
tantly, on the need for the drug to match the antihypertensive profile
of sitaxsentan and to be a clinically tolerable agent that is also a
standard treatment in CKD patients.21 A substudy evaluated the
effects of 100 mg of sitaxsentan once daily, placebo, and 30 mg of
nifedipine LA once daily on renal hemodynamics.
Subjects were randomly assigned to receive 100 mg of sitaxsen-
tan, matched placebo, or 30 mg of nifedipine LA once daily for 6
weeks, in addition to their usual medications. Each phase was
separated by a minimum 2-week washout period. Proteinuria, BP,
and arterial stiffness were assessed at baseline, week 3, and week 6
of each treatment period (Figure S1, available in the online Data
Supplement at http://hyper.ahajournals.org). Proteinuria was as-
sessed using both the mean 24-hour protein excretion and the mean
protein:creatinine ratio of 3 consecutive 24-hour urine collections.
Ambulatory BP was recorded at the brachial artery using a validated
SpaceLabs 90217 ambulatory BP monitor.22 Measurements were
taken every 30 minutes for 24 hours, and mean systolic BP, mean
arterial pressure (MAP), and diastolic BP were calculated. As
measures of arterial stiffness, pulse wave velocity (PWV) and central
augmentation index (cAIx) were recorded23 using the SphygmoCor
system (SphygmoCor Mx, AtCor Medical, version 6.31) and as-
sessed predose as described fully elsewhere.24 Safety data were
obtained at baseline and at weeks 1, 2, 3, 4, and 6 for each treatment
period. These included “office” BP, weight, hemoglobin, hematocrit,
liver enzymes, serum potassium, and adverse effects.
Renal Function Substudy
For those subjects taking part in the substudy, para-aminohippurate
sodium (PAH; Clinalfa) and Inutest (Fresenius Pharma) clearances
were used to assess renal blood flow and GFR, respectively, at
baseline and week 6 of each of the 3 study periods. These followed
our standard protocol and are described fully elsewhere.14,15
Plasma ET-1
Plasma ET-1 was measured at baseline, week 3, and week 6 of each
treatment period. After extraction,25 ET-1 was determined by
radioimmunoassay.26
Data and Statistical Analysis
Data were stored and analyzed using SAS version 8.2 or higher. The
planned sample size (an approximate target of 30 subjects to be
enrolled in the main study) was based primarily on logistical and
clinical considerations. However, data from a previous study14 using
an ETA receptor antagonist administered to 22 subjects in a crossover
design reported a reduction in proteinuria of up to496 g/min with
a SE of 141 g/min. This is 0.7 g/d with an SD of 0.9 g/d. Using
these data, it is possible to show that the current study size would
have 80% power to detect such a difference at the 2-sided 5%
significance level. Of the 30 subjects to be enrolled in the main
study, the aim was for 24 subjects to complete and 15 subjects
were to be included in the substudy, with the aim of 12 subjects
completing that. Similar calculations demonstrate that the substudy
had 50% power to detect statistically significant changes, but the
substudy was exploratory in nature, with the principal aim of
examining trends in the data.
For efficacy end points, the changes from baseline to week 6 and
from baseline to week 3 were analyzed using a mixed model with
repeated measures. The model was implemented using PROC
MIXED in SAS with terms for treatment group (fixed effect,
categorical variable), baseline value (fixed effect, continuous vari-
able, as appropriate for the end point), period effect (fixed effect,
categorical variable), week (the “repeated” effect), week-by-
treatment interaction, and subject-by-period interaction (the “sub-
ject” blocking effect). The model was fitted using restricted maxi-
mum likelihood estimation, and an autoregressive covariance
structure was implemented. Least squares means estimates for each
treatment and the treatment differences (100 mg of sitaxsentan minus
placebo; 100 mg of sitaxsentan minus 30 mg of nifedipine LA, and
30 mg of nifedipine LA minus placebo) were generated for weeks 3
and 6 from the treatment group-by-week interaction. Associated
SEMs and P values were calculated. The assumptions of the model
were checked by investigation of a normal probability plot of
standardized residuals and a plot of standardized residuals versus
fitted values. Carryover and sequence effects were explored by
adding these terms into the model (and removing if nonsignificant).
In addition, all of the data were summarized using simple summary
statistics (observed means, medians, and SDs). Percentage changes
were summarized for each treatment. Median differences between
treatments were calculated, and 95% CIs for the differences were
derived using the Hodges-Lehman estimator.
For the renal substudy, GFR and effective renal plasma flow were
calculated from inulin and para-aminohippurate sodium clearances,
respectively. Effective renal blood flow (ERBF) was calculated by
dividing effective renal plasma flow by (1hematocrit), and effec-
tive renal vascular resistance by dividing MAP by ERBF. Effective
filtration fraction (EFF) was defined as GFR/ERBF.
Dhaun et al Endothelin Antagonism and CKD 773
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Role of the Funding Source
This study was designed by the academic authors. The sponsor
was responsible for generating the subject randomization sched-
ule, gathering the data from the investigational site to create the
clinical database, and for data unblinding. On the basis of an
analysis plan developed in collaboration with the academic
authors, who also took responsibility for interpretation of the data
and for submitting this article for publication, the sponsor did the
data analysis. All of the authors had full access to study results
after unblinding the data.
Results
All 27 of the subjects completed all 3 phases of the study.
Patient diagnoses were IgA nephropathy (n14; 52%),
focal segmental glomerulosclerosis (n6; 22%), membra-
nous nephropathy (n3; 11%), hypertensive nephroscler-
osis (n2; 7%), reflux nephropathy, and microhematuria
of presumed glomerular origin (n1; 4%, for both), and 1
subject had an unknown cause for his or her CKD. Subject
baseline parameters are shown in Table 1. For all of the
subjects, baseline parameters did not differ among the 3
study phases.
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Figure 1. Effects of placebo, sitaxsentan, and nifedipine LA
(30 mg) on the coprimary end points of (A) 24-hours protein-
uria, and (B) PCR. Values are given as mean percentage of
change from baselineSEM at week 3 and week 6. Gray
block, placebo; hashed block, sitaxsentan; black block, nifed-
ipine. C, Effect of baseline protein excretion on maximal pro-
teinuria reduction (grams per day) with sitaxsentan (r20.67;
P0.01).
Table 1. Baseline Patient Characteristics for Main Study
and Substudy
Parameter
Main Study
(n27)
Substudy
(n13)
Demographic
Age, y 4812 4613
Male sex, n (%) 23 (85) 12 (92)
White, based on the subjects’ history 27 (100) 13 (100)
Clinical
Body mass index, kg/m2 29.34.6 28.24.7
Twenty-four–h BP, mm Hg
Systolic 12512 12710
Diastolic 787 808
Mean 9478 957
Creatinine, mg/dL* 1.730.85 1.720.76
Estimated GFR, mL/min per 1.73 m2 5426 5526
Hemoglobin, g/L 13618 13216
Serum potassium, mmol/L 4.60.4 4.60.4
Cholesterol, mg/dL† 17832 16838
Urinary protein excretion
g/24 h 2.031.7 2.011.6
PCR, mg/mmol 156143 150144
Arterial stiffness
PWV, m/s 8.32.4 7.41.4
AIx, % 2812 2414
Medications, n (%)
ACE inhibitor 18 (67) 10 (77)
ARB 11 (41) 3 (23)
ACE inhibitorARB 5 (19) 2 (15)
No ACE inhibitor or ARB 3 (11) 1 (8)
-Blocker 6 (22) 1 (8)
-Blocker 8 (30) 4 (31)
Calcium channel blocker 3 (11) 3 (23)
Diuretic 2 (7) 0 (0)
Statin 18 (67) 8 (62)
Values are given as mean of 3 baseline pretreatment periodsSD unless
otherwise specified.
*To convert to micromoles per liter, multiply by 88.4.
†To convert to millimoles per liter, multiply by 0.0259.
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Main Study (n27)
Sitaxsentan Versus Placebo
Proteinuria
Placebo was associated with no significant changes in 24-
hour urinary protein excretion or protein:creatinine ratio
(PCR) from baseline to week 3 or week 6. Sitaxsentan,
however, significantly reduced both 24-hour proteinuria and
PCR by 30% by study end (Figure 1). These effects of
sitaxsentan on proteinuria were apparent at week 3 of the
study period. The observed means (SD) for 24-hour pro-
teinuria were 2.071.77 g/d at baseline and 1.341.16 g/d at
week 6. For PCR these were 156147 and 109109 mg/
mmol. For 24-hour proteinuria, the least squares mean
changes (SEM) at week 6 were 0.730.14 g/d for
sitaxsentan and 0.090.14 g/d for placebo (P0.0001). For
PCR, these were 4810 and 8.610 mg/mmol
(P0.0002).
Sitaxsentan reduced proteinuria by 25% in 19 (70%)
of 27 subjects and by 40% in 9 (33%) of 27 subjects.
Only 2 subjects failed to show a reduction in 24-hour urine
protein excretion and only 1 in PCR. Furthermore, the
degree of proteinuria reduction closely related to the
baseline urinary protein excretion, with subjects with
higher baseline proteinuria achieving a greater reduction
(r20.67; P0.01). This effect was seen across all levels
of GFR (data not shown).
BP and Arterial Stiffness
Although placebo did not significantly affect MAP, systolic
BP, or diastolic BP between baseline and week 6 of the study
period, sitaxsentan reduced all 3 of the parameters by
5 mm Hg after 3 and 6 weeks dosing (Figure 2).
Placebo had no significant effects on PWV or cAIx over
the 6-week study period, whereas sitaxsentan reduced both by
study end. PWV fell by 5% compared with baseline, a
difference of 8% compared with placebo (Hodges-Lehman
95% CI: 16% to 2%; Figure 3).
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Figure 2. Effects of placebo, sitaxsentan, and nifedipine LA (30
mg) on 24-hour (A) mean arterial pressure, (B) systolic BP, and
(C) diastolic BP. Legend as for Figure 1.
A
-8
-6
-4
-2
0
2
4
6
8
week 3 week 6 week 3 week 6 week 3 week 6
%
 c
ha
ng
e 
fr
om
 b
as
el
in
e
B
-7
-6
-5
-4
-3
-2
-1
0
1
week 3 week 6 week 3 week 6 week 3 week 6
%
 c
ha
ng
e 
fr
om
 b
as
el
in
e
Sitaxsentan
Placebo 
Nifedipine
Figure 3. Effects of placebo, sitaxsentan, and nifedipine LA (30
mg) on (A) PWV and (B) cAIx. Legend as for Figure 1.
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Sitaxsentan Versus 30 mg of Nifedipine LA
After 6 weeks of dosing there were no significant differences
between sitaxsentan and nifedipine in the reductions from
baseline in BP parameters. Systolic BP was reduced by
4.31.2 versus4.41.2 mm Hg, diastolic BP by3.70.8
versus 2.70.8 mm Hg, and MAP by 3.90.9 versus
3.40.9 mm Hg (least squares meanSEM for sitaxsentan
and nifedipine, respectively). Despite this, sitaxsentan reduced
proteinuria to a significantly greater extent than nifedipine
(24-hour proteinuria: 0.610.14 versus 0.00.14 g/d,
P0.0033; PCR: 4310 versus 5.610 mg/mmol,
P0.0134). For sitaxsentan, the reduction in proteinuria corre-
lated with the fall in MAP at week 6 (r20.16; P0.04).
However, there were no relationships for the changes in protein-
uria and BP for the placebo and nifedipine phases. Although
PWV fell to a similar degree with nifedipine as with sitaxsentan
(0.40.2 versus 0.40.2 m/s), only sitaxsentan reduced
cAIx after 6 weeks of dosing.
All of the changes in proteinuria, BP, and arterial
stiffness had returned to baseline before starting the next
phase of the study (minimum 2 weeks). There were no
changes in plasma ET-1 concentrations with placebo,
sitaxsentan, or nifedipine.
Renal Substudy
ERBF did not change from day 0 to week 6 with placebo,
sitaxsentan, or nifedipine. Although GFR was similar at day
0 and week 6 with placebo and nifedipine, sitaxsentan
produced a substantial fall in GFR by week 6. EFF remained
unchanged between day 0 and week 6 with both placebo and
nifedipine. However, EFF was lower with sitaxsentan. This
was a consistent finding, with 12 of 13 subjects demonstrat-
ing a fall in EFF (n13; Table 2 and Figure 4). Ten subjects
had an EFF of 20% at baseline. These subjects showed a
fall of 2% (range: 2.1% to 8.9%) after 6 weeks of
sitaxsentan treatment. The 3 subjects with an EFF 20% at
baseline showed less impressive reductions in EFF after
sitaxsentan dosing. All of the changes in renal hemodynamics
had returned to baseline before starting the next phase of the
study (minimum 2 weeks).
Adverse Events
There was no difference in the overall incidence of adverse
events between the sitaxsentan and placebo groups (Table 3).
Of note, there was no significant weight gain (see Figure S1),
fall in hemoglobin or hematocrit, or rise in serum potassium
associated with sitaxsentan treatment compared with placebo.
Discussion
We have demonstrated that sitaxsentan, an oral selective ETA
receptor antagonist, reduces proteinuria, BP, and arterial
stiffness in patients with proteinuric nephropathy. These
effects were seen in patients already receiving optimal treat-
ment with ACE inhibitors and ARBs and were at least in part
BP independent. These findings suggest a potential role for
ETA receptor antagonism in conferring longer-term cardio-
vascular and renal benefits in patients with CKD.
Proteinuria reduction is important both for reducing risk of
CKD progression8 and associated CVD.3,4 However, despite
maximum achievable renin-angiotensin system blockade,
many patients with proteinuric CKD have significant residual
proteinuria.9 In the current study all of the subjects were
established on maximally tolerated treatment with ACE
Nifedipine
Baseline                 Week 6
Sitaxsentan
Baseline                  Week 6
Placebo
5
10
15
20
25
30
Baseline                  Week 6
%
Figure 4. Effect of placebo, sitaxsentan,
and nifedipine LA (30 mg) on EFF. Individ-
ual subject data are presented, as well as
the meanSEM at baseline and 6 weeks.
Table 2. Renal Substudy Data From Clearance Studies Performed at Baseline and Week 6 of
Each Study Period
Parameter
Placebo Sitaxsentan Nifedipine
Baseline Week 6 Baseline Week 6 Baseline Week 6
GFR, mL/min 567 548 578 488 598 589
ERBF, mL/min 53366 55265 51163 54373 56282 53072
ERVR, mm Hg/min per L 23052 20639 23644 23248 24858 25456
EFF, % 19.11.1 17.91.3 20.81.0 16.60.7 20.31.1 20.51.4
Values are given as predosing baselineSEM. GFR indicates glomerular filtration rate; ERBF, effective renal blood
flow; ERVR, effective renal vascular resistance; EFF, effective filtration fraction.
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inhibitors and/or ARBs with good BP control. Despite this,
mean baseline proteinuria was still significant at 2 g/d
(range: 0.3 to 7.8 g/d). Importantly, the data presented here
support a potential role for ET receptor antagonists as a novel
class of drug to help further reduce proteinuria in these
patients on top of standard therapy. This should have the
capacity to reduce CKD progression and the associated CVD,
morbidity, and mortality.
Interactions between the ET and renin-angiotensin systems
are well established.27–29 Furthermore, we have shown re-
cently that acute ETA receptor antagonism can reduce pro-
teinuria by an additional 30% on top of that achieved with
optimal treatment with inhibitors of the renin-angiotensin
system in subjects with proteinuric CKD.14 The current study
suggests that these effects are maintained longer term and are
of a similar magnitude. Interestingly, the size and time course
of this effect are similar to those seen with blockers of the
renin-angiotensin system.30–32 Furthermore, of those subjects
showing 40% reduction in urinary protein leak (9 of 27), 4
were on dual ACE inhibitor/ARB therapy, supporting a role
for ET receptor antagonists as adjunctive treatments for CKD
patients already established on renin-angiotensin system in-
hibitors. As has been shown previously with ACE inhibitors,8
the reduction in proteinuria was related to baseline protein-
uria, with subjects with a higher level of baseline urinary
protein leak achieving greater reductions. This effect was
seen across the range of renal function studied.
The effects of sitaxsentan on proteinuria described here are
likely explained by changes in both systemic and renal
hemodynamics. As expected, there was a correlation between
the reductions in BP and proteinuria after 6 weeks of
sitaxsentan dosing (r20.16; P0.04). However, sitaxsentan
also reduces proteinuria through BP-independent effects.
Other longer-term targets for selective ETA receptor antago-
nism include the podocyte, which has been implicated in the
development of proteinuria.13 In a recent study, the ET
receptor antagonist avosentan reduced macroalbuminuria in
subjects with diabetic nephropathy in the absence of a change
in BP.16 In the current study, our active control nifedipine
matched the fall in BP seen with sitaxsentan, but despite this,
sitaxsentan reduced proteinuria to a greater degree. Further-
more, for the reduction in BP seen with sitaxsentan
(4 mm Hg) a less impressive fall in proteinuria than the
observed at 30% would be expected. ACE inhibitors that
reduce proteinuria by a similar degree to the effect seen here
with sitaxsentan have more impressive effects on BP, reduc-
ing it by 10 mm Hg.20
Our substudy data support a renal hemodynamic mecha-
nism for the reduction in proteinuria seen with sitaxsentan.
ETA receptor antagonism had no effect on renal blood flow or
renal vascular resistance. However, as in previous studies,15,33
there was a very consistent fall in filtration fraction (4%),
suggesting that ET-1 induces an ETA receptor-mediated
preferential efferent arteriolar constriction. These effects are
analogous to, and occur in addition to, those seen with
renin-angiotensin system blockade. This postulated reduction
in efferent arteriolar tone with ETA receptor antagonism
should reduce glomerular perfusion pressure. This will result
in a reduction in proteinuria with an associated short-term fall
in GFR. Consistent with this proposed effect, we observed a
significant fall in GFR (9 mL/min) after 6 weeks of
sitaxsentan treatment. In patients already prescribed blockers
of the renin-angiotensin system, these effects, despite an
initial fall in GFR, should correlate with longer-term slowing
of the rate of CKD progression.
The current study confirms the concept that blocking the
ETA receptor reduces BP in CKD. Sitaxsentan reduced BP
modestly (a fall in MAP of4 mm Hg). This effect may have
been more impressive had the subjects not had such good
baseline BP control. Previous studies of the longer-term
antihypertensive effects of ET receptor antagonism suggest
that both selective ETA17,19 and mixed ETA/B antagonists20 are
effective at reducing BP in untreated hypertensive patients or
those with resistant hypertension. Our current data suggest
that, at least in patients with CKD, where BP control is often
difficult,11 ET receptor antagonism may provide a novel
strategy to lower BP to a greater extent than that achieved
with existing treatments.
Sitaxsentan also significantly improved arterial stiffness as
measured by PWV and cAIx compared with placebo. This is
likely to be attributable largely to the reduction in BP seen
with sitaxsentan.23 Interestingly, despite similar BP effects,
sitaxsentan reduced cAIx to a greater extent than nifedipine.
In the current study, unlike for BP and proteinuria, the
reductions in PWV and cAIx were higher at 6 weeks than
after 3 weeks of sitaxsentan treatment. It is possible that
longer treatment with an ETA receptor antagonist might
reduce PWV further and perhaps to a greater degree than
nifedipine. There are few clinical trials demonstrating that
differential lowering of PWV with medical treatment results
in different cardiovascular or renal outcomes,34,35 but the
importance of such studies is underscored by epidemiological
data, suggesting that PWV is an independent risk factor for
CVD morbidity and mortality.12,36
Six weeks of sitaxsentan dosing in subjects with varying
degrees of proteinuric CKD was not associated with any more
adverse events than placebo. Importantly, we observed no
weight gain, clinically significant edema, fall in hemoglobin
Table 3. Adverse Events Reported in the Study
Parameter
Placebo
(n27)
Sitaxsentan
(n27)
Nifedipine
(n27)
Adverse events, n 27 15 32
Subjects with adverse events, n (%) 21 (78) 13 (48) 18 (67)
Any serious adverse events, n (%) 0 (0) 0 (0) 0 (0)
Discontinuation because of adverse
events, n (%)
0 (0) 0 (0) 0 (0)
Adverse events reported 5%, n (%)
Headache 12 (48) 3 (11) 10 (37)
Nasal congestion 2 (7) 1 (4) 2 (7)
Flushing 0 (0) 1 (4) 2 (7)
Diarrhea 2 (7) 1 (4) 0 (0)
Nausea and vomiting 2 (7) 0 (0) 0 (0)
Back pain 2 (7) 0 (0) 2 (7)
Dizziness 2 (7) 1 (4) 1 (4)
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or hematocrit, or rise in serum potassium. Furthermore, the
changes in renal hemodynamics were not associated with
sodium retention (data not shown). Fluid retention has been
observed in several trials with ET receptor antagonists,
although its mechanism remains unclear. ET-1 acts in the
renal tubule via the ETB receptor to promote natriuresis and
diuresis.13 Thus, edema could be aggravated by mixed ETA/B
antagonists, and its absence in the current study may be
explained by the selective ETA blocking nature of our drug.
In addition, the careful selection of our subjects, excluding
those with clinically apparent CVD and overt heart failure
(and, thus, a propensity to fluid overload), may also help.
From a renal perspective, the lack of rise in serum potassium
with sitaxsentan is clinically significant, because this is a
troublesome adverse effect with both ACE inhibitors and
ARBs limiting their use.
Perspectives
We recognize some limitations to the current work. The study
was crossover by design. This may lead to subjects dropping
out, limiting its power, as well as having the issue of
carryover effects between different treatment phases. How-
ever, carryover was not a significant factor in the statistical
analysis, and the results from the main study clearly indicate
that the power was adequate. Subjects were optimized for
treatment of their proteinuria with ACE inhibitors and ARBs
but were not necessarily prescribed diuretics. These may
potentiate the antiproteinuric effects of renin-angiotensin
system blockade. Thus, the current data apply only to those
subjects not taking diuretics. Furthermore, although the small
study number is reasonable to show benefits of treatment,
much larger studies are required to highlight potentially
important but infrequent adverse events. In summary, the
current data support a role for selective ETA receptor antag-
onism as a novel and worthwhile therapeutic target in CKD to
lower proteinuria, BP, and arterial stiffness on top of standard
treatment, and on this basis, larger and longer-term studies
are now justified.
Addendum
Sitaxsentan has been voluntarily withdrawn by Pfizer, Ltd
due to unacceptable side effects. However, the findings in this
manuscript remain true for selective endothelin A receptor
antagonism.
Acknowledgments
We thank the study participants, as well as Neil Davie and Simon
Teal, for their continued support through the study.
Sources of Funding
N.D. was supported by the British Heart Foundation (project grant
PG/05/91) and National Health Service endowments. This study was
funded by Encysive Pharmaceuticals, Inc. In June 2008, Encysive
was acquired by Pfizer, Inc.
Disclosures
N.D., I.M.M., J.G., and D.J.W. have all received research grants
from Pfizer. N.D. and J.G. have held academic research fellowships
funded by educational grants from Pfizer. J.G. and D.J.W. have acted
as consultants to Pfizer. S.H. is an employee of Pfizer.
References
1. Meguid El Nahas A, Bello AK. Chronic kidney disease: the global
challenge. Lancet. 2005;365:331–340.
2. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL,
Klag MJ, Mailloux LU, Manske CL, Meyer KB, Parfrey PS, Pfeffer MA,
Wenger NK, Wilson PW, Wright JT Jr, for the National Kidney Foun-
dation Task Force on Cardiovascular Disease. Controlling the epidemic of
cardiovascular disease in chronic renal disease: what do we know? What
do we need to learn? Where do we go from here? Am J Kidney Dis.
1998;32:853–906.
3. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S,
Snapinn S, Cooper ME, Mitch WE, Brenner BM. Proteinuria, a target for
renoprotection in patients with type 2 diabetic nephropathy: lessons from
RENAAL. Kidney Int. 2004;65:2309–2320.
4. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S,
Snapinn S, Cooper ME, Mitch WE, Brenner BM. Albuminuria, a thera-
peutic target for cardiovascular protection in type 2 diabetic patients with
nephropathy. Circulation. 2004;110:921–927.
5. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH,
Mogensen CE, Dahlof B, Devereux RB, de Faire U, Fyhrquist F, Julius
S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil
S, Wan Y. Reduction in albuminuria translates to reduction in cardiovas-
cular events in hypertensive patients: Losartan Intervention for Endpoint
Reduction in Hypertension Study. Hypertension. 2005;45:198–202.
6. Levey AS, Cattran D, Friedman A, Miller WG, Sedor J, Tuttle K, Kasiske
B, Hostetter T. Proteinuria as a surrogate outcome in CKD: report of a
scientific workshop sponsored by the national kidney foundation and the
us food and drug administration. Am J Kidney Dis. 2009;54:205–226.
7. National Kidney Foundation. NKF K/DOQI guidelines. Available at:
http://www.kidney.org/professionals/KDOQI/guidelines_bp/guide_
9.htm. Accessed February 9, 2011.
8. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de
Zeeuw D, Shahinfar S, Toto R, Levey AS. Progression of chronic kidney
disease: the role of blood pressure control, proteinuria, and angiotensin-
converting enzyme inhibition: a patient-level meta-analysis. Ann Intern
Med. 2003;139:244–252.
9. Ruggenenti P, Perticucci E, Cravedi P, Gambara V, Costantini M, Sharma
SK, Perna A, Remuzzi G. Role of remission clinics in the longitudinal
treatment of CKD. J Am Soc Nephrol. 2008;19:1213–1224.
10. Coresh J, Wei GL, McQuillan G, Brancati FL, Levey AS, Jones C, Klag
MJ. Prevalence of high blood pressure and elevated serum creatinine level
in the United States: findings from the third National Health and Nutrition
Examination Survey (1988 –1994). Arch Intern Med. 2001;161:
1207–1216.
11. Peralta CA, Hicks LS, Chertow GM, Ayanian JZ, Vittinghoff E, Lin F,
Shlipak MG. Control of hypertension in adults with chronic kidney
disease in the United States. Hypertension. 2005;45:1119–1124.
12. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM.
Impact of aortic stiffness on survival in end-stage renal disease. Circu-
lation. 1999;99:2434–2439.
13. Dhaun N, Goddard J, Webb DJ. The endothelin system and its
antagonism in chronic kidney disease. J Am Soc Nephrol. 2006;17:
943–955.
14. Dhaun N, Macintyre IM, Melville V, Lilitkarntakul P, Johnston NR,
Goddard J, Webb DJ. Blood pressure-independent reduction in pro-
teinuria and arterial stiffness after acute endothelin-a receptor antagonism
in chronic kidney disease. Hypertension. 2009;54:113–119.
15. Goddard J, Johnston NR, Hand MF, Cumming AD, Rabelink TJ, Rankin
AJ, Webb DJ. Endothelin-A receptor antagonism reduces blood pressure
and increases renal blood flow in hypertensive patients with chronic renal
failure: a comparison of selective and combined endothelin receptor
blockade. Circulation. 2004;109:1186–1193.
16. Wenzel RR, Littke T, Kuranoff S, Jurgens C, Bruck H, Ritz E, Philipp T,
Mitchell A. Avosentan reduces albumin excretion in diabetics with mac-
roalbuminuria. J Am Soc Nephrol. 2009;20:655–664.
17. Weber MA, Black H, Bakris G, Krum H, Linas S, Weiss R, Linseman JV,
Wiens BL, Warren MS, Lindholm LH. A selective endothelin-receptor
antagonist to reduce blood pressure in patients with treatment-resistant
hypertension: a randomised, double-blind, placebo-controlled trial.
Lancet. 2009;374:1423–1431.
778 Hypertension April 2011
 by guest on May 3, 2014http://hyper.ahajournals.org/Downloaded from 
18. K/DOQI clinical practice guidelines for chronic kidney disease: eval-
uation, classification and stratification. Am J Kidney Dis. 2002;39:1–266.
19. Nakov R, Pfarr E, Eberle S. Darusentan: an effective endothelin A
receptor antagonist for treatment of hypertension. Am J Hypertens. 2002;
15:583–589.
20. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V. The effect
of an endothelin-receptor antagonist, bosentan, on blood pressure in
patients with essential hypertension. N Engl J Med. 1998;338:784–790.
21. de Leeuw PW, Ruilope LM, Palmer CR, Brown MJ, Castaigne A, Mancia
G, Rosenthal T, Wagener G. Clinical significance of renal function in
hypertensive patients at high risk: results from the INSIGHT Trial. Arch
Intern Med. 2004;164:2459–2464.
22. Baumgart P, Kamp J. Accuracy of the SpaceLabs Medical 90217 ambu-
latory blood pressure monitor. Blood Press Monit. 1998;3:303–307.
23. Oliver JJ, Webb DJ. Noninvasive assessment of arterial stiffness and risk
of atherosclerotic events. Arterioscler Thromb Vasc Biol. 2003;23:
554–566.
24. Oliver JJ, Melville VP, Webb DJ. Effect of regular phosphodiesterase
type 5 inhibition in hypertension. Hypertension. 2006;48:622–627.
25. Rolinski B, Bonger SJ, Goebel FD. Determination of endothelin-1 immu-
noreactivity in plasma, cerebrospinal fluid and urine. Res Exp Med.
1994;194:9–24.
26. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin
correlates with the extent of pulmonary hypertension in patients with
chronic congestive heart failure. Circulation. 1992;85:504–509.
27. Rossi GP, Sacchetto A, Cesari M, Pessina AC. Interactions between the
endothelin-1 and the renin-angiotensin-aldosterone system. Cardiovasc
Res. 1999;43:300–307.
28. Goddard J, Eckhart C, Johnston NR, Cumming AD, Rankin AJ, Webb
DJ. Endothelin A receptor antagonism and angiotensin-converting
enzyme inhibition are synergistic via an endothelin B receptor-mediated
and nitric oxide-dependent mechanism. J Am Soc Nephrol. 2004;15:
2601–2610.
29. Montanari A, Carra N, Perinotto P, Iori V, Fasoli E, Biggi A, Novarini A.
Renal hemodynamic control by endothelin and nitric oxide under angio-
tensin II blockade in man. Hypertension. 2002;39:715–720.
30. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S,
Arner P. The effect of irbesartan on the development of diabetic nephrop-
athy in patients with type 2 diabetes. N Engl J Med. 2001;345:870–878.
31. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren
combined with losartan in type 2 diabetes and nephropathy. N Engl
J Med. 2008;358:2433–2446.
32. Persson F, Rossing P, Schjoedt KJ, Juhl T, Tarnow L, Stehouwer CD,
Schalkwijk C, Boomsma F, Frandsen E, Parving HH. Time course of the
antiproteinuric and antihypertensive effects of direct renin inhibition in
type 2 diabetes. Kidney Int. 2008;73:1419–1425.
33. Dhaun N, Ferro CJ, Davenport AP, Haynes WG, Goddard J, Webb DJ.
Haemodynamic and renal effects of endothelin receptor antagonism in
patients with chronic kidney disease. Nephrol Dial Transplant. 2007;22:
3228–3234.
34. Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM.
Impact of aortic stiffness attenuation on survival of patients in end-stage
renal failure. Circulation. 2001;103:987–992.
35. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D,
Hughes AD, Thurston H, O’Rourke M. Differential impact of blood
pressure-lowering drugs on central aortic pressure and clinical outcomes:
principal results of the Conduit Artery Function Evaluation (CAFE)
Study. Circulation. 2006;113:1213–1225.
36. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, Duci-
metiere P, Benetos A. Aortic stiffness is an independent predictor of all-cause
and cardiovascular mortality in hypertensive patients. Hypertension. 2001;
37:1236–1241.
Dhaun et al Endothelin Antagonism and CKD 779
 by guest on May 3, 2014http://hyper.ahajournals.org/Downloaded from 
Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure & arterial 
stiffness in chronic proteinuric kidney disease 
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